Why Is AARD Stock Dropping Today? Aardvark Therapeutics Falls After Trial Pause, Data Delay

Aardvark Therapeutics (AARD) shares fell approximately 14.7% in pre-market trading on Monday after the company disclosed a voluntary pause of its late-stage ARD-101 trial and a delay to its HERO trial data readout. The update removes two near-term catalysts for the development-stage biotech.

What Happened With The Clinical Trials?

The company paused the ARD-101 study in Prader-Willi Syndrome after identifying cardiac safety signals in trial participants. ARD-101 is Aardvark's lead drug candidate, designed to target hyperphagia — the excessive hunger that drives severe obesity in PWS patients.

Separately, Aardvark said it no longer expects to release topline data from its HERO trial in the third quarter of 2026. The company had previously guided to a Q3 readout, making the delay a material shift in its development timeline.

Both updates appeared to come via an SEC filing, according to reports from MarketWatch and Yahoo Finance.

Why Does The Setback Matter For Aardvark?

For a clinical-stage biotech, the pipeline is the investment thesis. ARD-101 is the lead asset, and a voluntary pause tied to cardiac safety introduces new uncertainty about the drug's risk profile and ultimate approvability — even though the company initiated the pause rather than the FDA.

The HERO trial delay compounds the pressure. With the lead program on hold and the next data catalyst now pushed beyond Q3, the near-term news flow has thinned considerably. Investors in pre-revenue biotech companies depend on clinical readouts to validate the science, and losing two near-term catalysts in a single disclosure is a material setback.

What Should Investors Watch Next?

Regular-session trading will be the first real test of institutional sentiment. Pre-market moves can be amplified by thinner liquidity and wider spreads, so the stock may reprice as more participants engage during the regular session.

Beyond the immediate price action, investors will look for the company to provide more detail on the nature of the cardiac safety signals — including whether the issue is drug-related or tied to the underlying patient population — and a revised timeline for the HERO trial readout. Analyst downgrades or price-target cuts are a near-term risk given the dual setbacks and the removal of two key catalysts from the calendar.